Sensirion Announces Global Availability of SFM3304-D Single-Use Flow Sensor
Sensirion has launched the SFM3304-D, a single-use gas flow sensor designed for proximal flow measurement in mechanical ventilation and respiratory applications.
Stocks · News reference
Senseonics Initiates First-in-Human Clinical Study for Freedom CGM System
Senseonics Holdings, Inc. has commenced the first-in-human clinical study for its investigational 'Freedom' continuous glucose monitoring (CGM) system, which is designed to operate without an external on-body transmitter.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Senseonics Initiates First-in-Human Study of Freedom, Designed to be the World’s First CGM System with No On-body Component
Senseonics announced the initiation of its first-in-human clinical study for Freedom, an investigational next-generation continuous glucose monitoring (CGM) system designed to communicate directly with mobile devices without an external transmitter. Built on proven Eversense 365 technology and supported by encouraging preclinical data, Freedom aims for potential commercial launch in 2028, with a pivotal study expected to begin in 2027.
Senseonics Holdings, Inc. Announces Participation in November 2026 Investor Conferences
Senseonics management will participate in the Stifel 2026 Healthcare Conference and the 20th Annual Canaccord Genuity MedTech, Diagnostics & Digital Health Forum in November.